Assessment of Plasmodium falciparum resistance to ferroquine (SSR97193) in field isolates and in W2 strain under pressure
2006

Study on Ferroquine Resistance in Malaria

Sample size: 33 publication Evidence: moderate

Author Information

Author(s): Wassim Daher, Christophe Biot, Thierry Fandeur, Helene Jouin, Lydie Pelinski, Eric Viscogliosi, Laurent Fraisse, Bruno Pradines, Jacques Brocard, Jamal Khalife, Daniel Dive

Primary Institution: Inserm U547, Institut Pasteur, Lille, France

Hypothesis

Can Plasmodium falciparum develop resistance to the new antimalarial drug ferroquine?

Conclusion

Ferroquine effectively overcomes chloroquine resistance in malaria parasites, indicating its potential as a new treatment.

Supporting Evidence

  • Ferroquine was found to be equally active on both chloroquine-sensitive and resistant strains.
  • Transient survival of the W2 strain under drug pressure was observed in only one of two experiments.
  • IC50 values for ferroquine in field isolates were unrelated to mutations in the PfCRT gene.

Takeaway

This study looked at how well a new malaria drug called ferroquine works against resistant malaria parasites. It found that the drug is likely to be effective.

Methodology

The study assessed the relationship between chloroquine resistance and susceptibility to ferroquine in 33 Cambodian field isolates and the W2 strain under drug pressure.

Limitations

The study was limited to a small sample size of field isolates and may not represent all populations.

Participant Demographics

The study focused on Cambodian P. falciparum field isolates.

Digital Object Identifier (DOI)

10.1186/1475-2875-5-11

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication